Literature DB >> 26608499

Cytokines and matrix metalloproteinases in the cerebrospinal fluid of patients with acute transverse myelitis: an outcome analysis.

Puneet Dixit1, Ravindra Kumar Garg2, Hardeep Singh Malhotra1, Amita Jain3, Rajesh Verma1, Praveen Kumar Sharma1, Neeraj Kumar1.   

Abstract

BACKGROUND: Role of cytokines as well as matrix metalloproteinases (MMPs) is well defined in various central nervous system inflammatory diseases. However, the role of these cytokines and MMPs in acute transverse myelitis is inadequately studied.
MATERIALS AND METHODS: Patients with acute transverse myelitis, fulfilling the inclusion and exclusion criteria defined by Transverse Myelitis Consortium Working Group, were enrolled along with age and sex matched controls. A detailed clinical evaluation and magnetic resonance imaging of patients was done. Cerebrospinal fluid (CSF) samples both from patients and controls were collected. CSF samples were analyzed for cytokines [interleukin (IL)-6, IL-8, IL-10 and IL-17)] and matrix metalloproteinases (MMP-2, MMP-9). Patients were followed up for 3 months. Disability was assessed using modified Barthel index (MBI).
RESULTS: CSF levels of all cytokines IL-6, IL-8, IL-10, MMP-2 and MMP-9, except IL-17, were significantly higher in patients with acute transverse myelitis (p < 0.001). CSF IL-6 and IL-8 were significantly associated with severity of the disease (MBI ≤ 12). After 3 months, quadriparesis (p = 0.001, odd's ratio 19.5, 95 % CI 2.34-62.39) and long-segment myelitis (p = 0.035, odd's ratio 4.37, 95 % CI 1.17-5.95) were significantly associated with poor outcome. Among cytokines and MMPs, IL-6 levels at baseline correlated significantly with the MBI at 3 months (Spearmen's ρ = -0.335, p = 0.01).
CONCLUSION: In conclusion, both anti-inflammatory and pro-inflammatory cytokines, MMP-2, and MMP-9 are elevated in the acute phase of transverse myelitis. Possibly, IL-6 plays a role in determining the disability.

Entities:  

Keywords:  Cerebrospinal fluid; Cytokines; Interleukin; Longitudinally extensive transverse myelitis; Matrix metalloproteinases

Mesh:

Substances:

Year:  2015        PMID: 26608499     DOI: 10.1007/s00011-015-0896-8

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  18 in total

1.  Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 cases.

Authors:  J Bruna; S Martínez-Yélamos; A Martínez-Yélamos; F Rubio; T Arbizu
Journal:  Mult Scler       Date:  2006-04       Impact factor: 6.312

2.  Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6.

Authors:  Akiyuki Uzawa; Masahiro Mori; Kimihito Arai; Yasunori Sato; Sei Hayakawa; Saeko Masuda; Junko Taniguchi; Satoshi Kuwabara
Journal:  Mult Scler       Date:  2010-08-25       Impact factor: 6.312

3.  Increased serum matrix metalloproteinase-9 in neuromyelitis optica: implication of disruption of blood-brain barrier.

Authors:  Takafumi Hosokawa; Hideto Nakajima; Yoshimitsu Doi; Masakazu Sugino; Fumiharu Kimura; Toshiaki Hanafusa; Toshiyuki Takahashi
Journal:  J Neuroimmunol       Date:  2011-05-31       Impact factor: 3.478

Review 4.  Diagnosis and management of acute myelopathies.

Authors:  Adam I Kaplin; Chitra Krishnan; Deepa M Deshpande; Carlos A Pardo; Douglas A Kerr
Journal:  Neurologist       Date:  2005-01       Impact factor: 1.398

Review 5.  Proposed diagnostic criteria and nosology of acute transverse myelitis.

Authors: 
Journal:  Neurology       Date:  2002-08-27       Impact factor: 9.910

Review 6.  Matrix metalloproteinases in neuroinflammation.

Authors:  Gary A Rosenberg
Journal:  Glia       Date:  2002-09       Impact factor: 7.452

Review 7.  Transverse Myelitis: pathogenesis, diagnosis and treatment.

Authors:  Chitra Krishnan; Adam I Kaplin; Deepa M Deshpande; Carlos A Pardo; Douglas A Kerr
Journal:  Front Biosci       Date:  2004-05-01

Review 8.  Transverse myelitis spectrum disorders.

Authors:  Lekha Pandit
Journal:  Neurol India       Date:  2009 Mar-Apr       Impact factor: 2.117

9.  The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients.

Authors:  Ulisses C Linhares; Patrícia B Schiavoni; Priscila O Barros; Taissa M Kasahara; Bruna Teixeira; Thais B Ferreira; Regina Alvarenga; Joana Hygino; Morgana M M Vieira; Vera Carolina B Bittencourt; Regis M Andrade; Arnaldo F Andrade; Cleonice A M Bento
Journal:  J Clin Immunol       Date:  2012-09-05       Impact factor: 8.317

10.  Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases.

Authors:  Alexandre Wullschleger; Viktoria Kapina; Nicolas Molnarfi; Delphine S Courvoisier; Jörg D Seebach; Marie-Laure Santiago-Raber; Denis F Hochstrasser; Patrice H Lalive
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

View more
  2 in total

1.  Fulminant Acute Ascending Hemorrhagic Myelitis Treated with Eculizumab.

Authors:  Nang Boe Ohnmar Hsam; Klemens Angstwurm; Sebastian Peters; Kornelius Fuchs; Gerhard Schuierer; Ulrich Bogdahn; Robert Weissert
Journal:  Front Neurol       Date:  2017-07-27       Impact factor: 4.003

Review 2.  Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.

Authors:  Michael R Pranzatelli
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.